INMUNE BIO INC. Deferred Tax Assets, Tax Deferred Expense
INMUNE BIO INC. (INMB) had Deferred Tax Assets, Tax Deferred Expense of $25.69 million as of 2024-12-31, per its 10-K filed 2025-03-27.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense
us-gaap:DeferredTaxAssetsTaxDeferredExpense · last filed 2025-03-27
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense $25.69M.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense $19.61M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense $13.73M.
| Period end | Deferred Tax Assets, Tax Deferred Expense |
|---|---|
| 2024-12-31 | $25.69M 10-K · filed 2025-03-27 |
| 2023-12-31 | $19.61M 10-K · filed 2025-03-27 |
| 2022-12-31 | $13.73M 10-K · filed 2024-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B |